Methyclothiazide NEW
| Price | $30 | Get Latest Price | Get Latest Price |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Methyclothiazide | CAS No.: 135-07-9 |
| Purity: 99.13% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Methyclothiazide |
| Description | Methyclothiazide (Aquatensen) is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various conditions including heart disease. |
| In vitro | Methyclothiazide (0.1 mM) reduces Ca2+ contractures with maximal inhibition of 90.4% in SHR aortic rings with endothelium. The inhibitory effect of Methyclothiazide (0.1 mM) on Ca2+ contracture is significantly but not totally abolished by the NO synthase inhibitor in SHR aortic rings with functional endothelium. [1] Methyclothiazide (0.1 mM) induces endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP only in aortas from spontaneously hypertensive rats (SHR) rather than normotensive Wistar Kyoto rats (WKY), and the maximal vasoconstrictive effect of NE and AVP is decreased by 59% and 32.3%, respectively. [2] Methyclothiazide (3.5 mM) inhibits renin release in rat kidney slices. [3] |
| In vivo | Methyclothiazide (0.1 g/L for the first 5 weeks and 0.2 g/L for the second 2 weeks, drinking water) attenuates development of hypertension in salt-sensitive (DS) rats, but does not affect blood pressure in salt-resistant (DR) ones. [4] The methyclothiazide-treated DOCA-salt rats weigh less than controls or the nonsupplemented DOCA-salt rats at weeks 3 and 4. Methyclothiazide added to the drinking water of DOCA-salt rats attenuates the elevation of blood pressure. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 72 mg/mL (199.86 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 4 mg/mL (11.1 mM) |
| Keywords | Carbonic Anhydrase | Methyclothiazide | ?stroke,?heart attack,thiazide diuretics | Inhibitor | inhibit | edema | blood | high | pressure | Carbonate dehydratase |
| Inhibitors Related | Benzenesulfonamide | Urea | Cyclamic acid sodium | Orthanilamide | Tioxolone | pNNP |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00/1g |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-08 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-08 | |
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY